Theravance Biopharma, Inc.Theravance Biopharma, Inc.Theravance Biopharma, Inc.

Theravance Biopharma, Inc.

No trades
See on Supercharts
Market capitalization
‪458.53 M‬USD
−0.97USD
‪−55.19 M‬USD
‪57.42 M‬USD
‪43.68 M‬
Beta (1Y)
0.35

About Theravance Biopharma, Inc.

CEO
Rick E. Winningham
Headquarters
South San
Employees (FY)
99
Founded
2013
ISIN
KYG8807B1068
FIGI
BBG004HK6YX1
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of TBPH is 9.20 USD — it has decreased by 3.36% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Theravance Biopharma, Inc. stocks are traded under the ticker TBPH.
Theravance Biopharma, Inc. is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
TBPH stock is 4.04% volatile and has beta coefficient of 0.35. Check out the list of the most volatile stocks — is Theravance Biopharma, Inc. there?
One year price forecast for Theravance Biopharma, Inc. has a max estimate of 21.00 USD and a min estimate of 10.00 USD.
TBPH earnings for the last quarter are −0.17 USD whereas the estimation was −0.21 USD which accounts for 19.05% surprise. Estimated earnings for the next quarter are −0.15 USD. See more details about Theravance Biopharma, Inc. earnings.
Theravance Biopharma, Inc. revenue for the last quarter amounts to ‪15.69 M‬ USD despite the estimated figure of ‪15.40 M‬ USD. In the next quarter revenue is expected to reach ‪17.57 M‬ USD.
Yes, you can track Theravance Biopharma, Inc. financials in yearly and quarterly reports right on TradingView.
TBPH stock has fallen by 3.16% compared to the previous week, the month change is a 6.24% rise, over the last year Theravance Biopharma, Inc. has showed a 20.69% decrease.
TBPH net income for the last quarter is ‪−8.51 M‬ USD, while the quarter before that showed ‪−8.95 M‬ USD of net income which accounts for 4.91% change. Track more Theravance Biopharma, Inc. financial stats to get the full picture.
Today Theravance Biopharma, Inc. has the market capitalization of ‪458.53 M‬, it has increased by 4.07% over the last week.
No, TBPH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TBPH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Theravance Biopharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
TBPH reached its all-time high on Jun 26, 2017 with the price of 43.44 USD, and its all-time low was 6.10 USD and was reached on Sep 15, 2021.
See other stocks reaching their highest and lowest prices.
As of Apr 19, 2024, the company has 99.00 employees. See our rating of the largest employees — is Theravance Biopharma, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Theravance Biopharma, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Theravance Biopharma, Inc. stock shows the sell signal. See more of Theravance Biopharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Theravance Biopharma, Inc. future price: according to them, TBPH price has a max estimate of 21.00 USD and a min estimate of 10.00 USD. Read a more detailed Theravance Biopharma, Inc. forecast: see what analysts think of Theravance Biopharma, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Theravance Biopharma, Inc. EBITDA is ‪−47.24 M‬ USD, and current EBITDA margin is −82.27%. See more stats in Theravance Biopharma, Inc. financial statements.